Fatemeh Motamedi Dehbarez, Navid Nezafat and Shirin Mahmoodi* Pages 1164 - 1176 ( 13 )
Background: Hepatocellular Carcinoma (HCC) is a prevalent cancer in the world. As yet, there is no medication for complete treatment of HCC.Objective: There is a critical need to search for an innovative therapy for HCC. Recently, multiepitope vaccines have been introduced as effective immunotherapy approach against HCC. Methods: In this research, several immunoinformatics methods were applied to create an original multi-epitope vaccine against HCC consisting of CD8+ cytolytic T lymphocytes (CTLs) epitopes selected from α- fetoprotein (AFP), glypican-3 (GPC3), aspartyl-β-hydroxylase (ASPH); CD4+ helper T lymphocytes (HTLs) epitopes from tetanus toxin fragment C (TTFC), and finally, two tandem repeats of HSP70407-426 were used which stimulated strong innate and adaptive immune responses. All the mentioned parts were connected together by relevant linkers. Results and Discussions: According to physicochemical, structural, and immunological results, the designed vaccine is stable, non-allergen, antigen; it also has a high-quality 3D structure, and numerous linear and conformational B cell epitopes, whereby this vaccine may stimulate efficient humoral immunity. Conclusion: Center on the collected results, the designed vaccine potentially can induce cellular and humoral immune responses in HCC cases; nonetheless, the efficiency of vaccine must be approved within in vitro and in vivo immunological analyzes.
Hepatocellular carcinoma, immunoinformatics, multi-epitope vaccine, adjuvant, immunotherapy, linker.
Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa